Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Director departure
|
|
eFFECTOR Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 05/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 05/25/2023 |
8-K
| Other Events Interactive Data |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/09/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/05/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 11/07/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/14/2022 |
8-K
| Other Events Interactive Data |
| 09/01/2022 |
8-K
| Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T... |
| 07/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/10/2022 |
8-K
| Quarterly results |
| 06/06/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/28/2022 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 03/16/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/16/2022 |
8-K
| Resignation/termination of a director |
| 01/24/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ... |
| 11/08/2021 |
8-K
| Quarterly results |
| 11/01/2021 |
8-K
| Resignation/termination of a director |
| 08/31/2021 |
8-K
| Director compensation was amended/approved|
Docs:
|
"Amended and Restated Certificate of Incorporation of eFFECTOR Therapeutics, Inc",
"Amended and Restated Bylaws of eFFECTOR Therapeutics, Inc",
"Amended and Restated Registration Rights Agreement, by and among eFFECTOR Therapeutics, Inc., eFFECTOR Therapeutics Operations, Inc., Locust Walk Sponsor, LLC and certain stockholders",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter Agreement, by and among Locust Walk Acquisition Corp. and certain security holders, officers and directors of Locust Walk Acquisition Corp. (incorporated by reference to of the Registrant’s Form 8-K, filed with the SEC on January 13, 2021)",
"Letter from WithumSmith+Brown, PC to the Securities and Exchange Commission",
"Unaudited condensed financial information of Old eFFECTOR as of and for the three and six months ended June 30, 2021",
"Management’s Discussion and Analysis of Financial Condition and Results of Operations of Old eFFECTOR" |
|
| 08/24/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 08/23/2021 |
8-K
| Other Events Interactive Data |
| 06/03/2021 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...|
Docs:
|
"Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading Symbols Name of each exchange on which registered Class A Common Stock, par value $0.0001 per share LWAC Nasdaq Capital Market Warrants to purchase one share of Class A Common Stock LWACW Nasdaq Capit...",
"Locust Walk Acquisition Corp. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q Stemming from SEC Guidance Concerning Balance Sheet Treatment of Warrants BOSTON, MA, June 3, 2021 - Locust Walk Acquisition Corp. , a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that on May 28, 2021 it received a notice from Nasdaq Regulation indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 , the Company is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission . The Nasdaq notice has no immediate effec..." |
|
| 05/27/2021 |
8-K
| Director compensation was amended/approved|
Docs:
|
"United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 May 26, 2021 Date of Report Locust Walk Acquisition Corp. Delaware 001-39866 85-3306396 200 Clarendon Street, 51st Floor, Boston, MA 02116 Registrant's telephone number, including area code: 697-0763 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☒ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ☐ Pre-commencement...",
"Agreement and Plan of Merger, by and among Locust Walk Acquisition Corp., Locust Walk Merger Sub, Inc. and eFFECTOR Therapeutics, Inc",
"Sponsor Support Agreement by and among Locust Walk Sponsor, LLC, eFFECTOR Therapeutics, Inc. and Locust Walk Acquisition Corp",
"Sponsor Lock-up Agreement by and between Locust Walk Sponsor, LLC and Locust Walk Acquisition Corp",
"Form of Subscription Agreement",
"Form of Amended and Restated Registration Rights Agreement",
"eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies",
"Investor Presentation",
"Investor Presentation",
"Script for Investor Webcast" |
|
| 01/19/2021 |
8-K
| Quarterly results |
| 01/13/2021 |
8-K
| Quarterly results |
|
|